495 related articles for article (PubMed ID: 30872102)
41. [Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].
Xue S; Lu H; Tang L; Fang J; Shi L; Li J; Yu Y; Zhou Q; Xue S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):50-55. PubMed ID: 32148231
[TBL] [Abstract][Full Text] [Related]
42. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.
Rodvold KA; Pryka RD; Garrison M; Rotschafer JC
Ther Drug Monit; 1989; 11(3):269-75. PubMed ID: 2728085
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
46. Individualized Delivery of Vancomycin by Model-Informed Bayesian Dosing Approach to Maintain an AUC24 Target in Critically Ill Patients.
Rao Z; Guo SM; Wei YM
Chemotherapy; 2024; 69(1):49-55. PubMed ID: 37591210
[TBL] [Abstract][Full Text] [Related]
47. Dosing vancomycin in the super obese: less is more.
Crass RL; Dunn R; Hong J; Krop LC; Pai MP
J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
[TBL] [Abstract][Full Text] [Related]
48. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.
Wrishko RE; Levine M; Khoo D; Abbott P; Hamilton D
Ther Drug Monit; 2000 Oct; 22(5):522-31. PubMed ID: 11034256
[TBL] [Abstract][Full Text] [Related]
49. Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.
Pai MP; Hong J; Krop L
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096158
[TBL] [Abstract][Full Text] [Related]
50. Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
Schatz LM; Brinkmann A; Röhr A; Frey O; Greppmair S; Weinelt F; Zoller M; Scharf C; Hempel G; Liebchen U
Antimicrob Agents Chemother; 2023 May; 67(5):e0010423. PubMed ID: 37125925
[TBL] [Abstract][Full Text] [Related]
51. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
[TBL] [Abstract][Full Text] [Related]
52. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.
Li J; Udy AA; Kirkpatrick CM; Lipman J; Roberts JA
Int J Antimicrob Agents; 2012 Jan; 39(1):69-72. PubMed ID: 22024354
[TBL] [Abstract][Full Text] [Related]
53. Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients.
Ter Heine R; Keizer RJ; van Steeg K; Smolders EJ; van Luin M; Derijks HJ; de Jager CPC; Frenzel T; Brüggemann R
Br J Clin Pharmacol; 2020 Dec; 86(12):2497-2506. PubMed ID: 32415710
[TBL] [Abstract][Full Text] [Related]
54. Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy.
Oda K; Jono H; Kamohara H; Nishi K; Tanoue N; Saito H
Pharm Res; 2020 May; 37(6):108. PubMed ID: 32468340
[TBL] [Abstract][Full Text] [Related]
55. Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.
Elbarbry F
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):259-268. PubMed ID: 29260505
[TBL] [Abstract][Full Text] [Related]
56. Vancomycin monitoring in children using bayesian estimation.
Le J; Ngu B; Bradley JS; Murray W; Nguyen A; Nguyen L; Romanowski GL; Vo T; Capparelli EV
Ther Drug Monit; 2014 Aug; 36(4):510-8. PubMed ID: 24452067
[TBL] [Abstract][Full Text] [Related]
57. Use of a common spreadsheet program to demonstrate the ability of Bayesian forecasting to estimate the pharmacokinetic parameters of antibiotics.
Brocks DR; Wang M
J Pharm Pharmacol; 2023 Oct; 75(10):1378-1387. PubMed ID: 37478874
[TBL] [Abstract][Full Text] [Related]
58. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors.
Hughes JH; Keizer RJ
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1150-1160. PubMed ID: 34270885
[TBL] [Abstract][Full Text] [Related]
59. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
60. Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: A simulation study.
Oda K; Yamada T; Matsumoto K; Hanai Y; Ueda T; Samura M; Shigemi A; Jono H; Saito H; Kimura T
Clin Transl Sci; 2023 Nov; 16(11):2265-2275. PubMed ID: 37718491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
